Kymera Therapeutics, Inc. (KYMR)

NGM – Real vaqt narxi. Valyuta: USD

112.55

+2.93 (2.67%)

Bozor ochiq: Aug 12, 2026, 1:53 PM EDT

109.62

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

06.08.2026

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

05.08.2026

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

05.08.2026

Kymera Therapeutics Q2 Earnings Call Highlights

Kymera Therapeutics NASDAQ: KYMR said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and potentially begin Phase 3 development around mid-2027.

05.08.2026

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.

05.08.2026

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26 KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi Well-capitalized with $1.5 billion in cash as of June 30, 2026, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
KYMR	Deutsche Bank	Hold	undefined >> $120	July 30th 2026

Press-relizlar

05.08.2026

Kymera Therapeutics, Inc. (KYMR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Kymera Therapeutics, Inc. (KYMR)

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics Q2 Earnings Call Highlights

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics Q2 Earnings Call Highlights

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Search stocks

Kymera Therapeutics, Inc. (KYMR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Kymera Therapeutics, Inc. (KYMR)

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics Q2 Earnings Call Highlights

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics Q2 Earnings Call Highlights

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update